563 related articles for article (PubMed ID: 14969807)
1. PSA relapse prostate cancer: the importance of tailored therapy.
Aranha O; Vaishampayan U
Urol Oncol; 2004; 22(1):62-9. PubMed ID: 14969807
[TBL] [Abstract][Full Text] [Related]
2. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy.
Bianco FJ; Scardino PT; Stephenson AJ; Diblasio CJ; Fearn PA; Eastham JA
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):448-53. PubMed ID: 15890586
[TBL] [Abstract][Full Text] [Related]
3. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
4. Prostate specific antigen doubling time after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy.
Rabbani F; Perrotti M; Bastar A; Fair WR
J Urol; 1999 Mar; 161(3):847-52. PubMed ID: 10022699
[TBL] [Abstract][Full Text] [Related]
5. The value of radiotherapy in treating recurrent prostate cancer after radical prostatectomy.
Stephenson AJ; Slawin KM
Nat Clin Pract Urol; 2004 Dec; 1(2):90-6. PubMed ID: 16474521
[TBL] [Abstract][Full Text] [Related]
6. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.
Simmons MN; Stephenson AJ; Klein EA
Eur Urol; 2007 May; 51(5):1175-84. PubMed ID: 17240528
[TBL] [Abstract][Full Text] [Related]
7. Prostate specific antigen recurrence after definitive therapy.
Freedland SJ; Moul JW
J Urol; 2007 Jun; 177(6):1985-91. PubMed ID: 17509277
[TBL] [Abstract][Full Text] [Related]
8. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
9. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
[TBL] [Abstract][Full Text] [Related]
10. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy.
King CR; Presti JC; Brooks JD; Gill H; Spiotto MT
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1472-7. PubMed ID: 17935902
[TBL] [Abstract][Full Text] [Related]
11. Rising prostate-specific antigen after primary prostate cancer therapy.
Ward JF; Moul JW
Nat Clin Pract Urol; 2005 Apr; 2(4):174-82. PubMed ID: 16474760
[TBL] [Abstract][Full Text] [Related]
12. Early outcomes of active surveillance for localized prostate cancer.
Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
[TBL] [Abstract][Full Text] [Related]
13. Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer.
Naito S
Jpn J Clin Oncol; 2005 Jul; 35(7):365-74. PubMed ID: 15976063
[TBL] [Abstract][Full Text] [Related]
14. Radical prostatectomy for clinical stage T3a disease.
Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
[TBL] [Abstract][Full Text] [Related]
15. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy.
Sandler HM; Eisenberger MA
J Urol; 2007 Sep; 178(3 Pt 2):S20-4. PubMed ID: 17644123
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
17. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
D'Amico A
BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy.
Bajaj GK; Zhang Z; Garrett-Mayer E; Drew R; Sinibaldi V; Pili R; Denmeade SR; Carducci MA; Eisenberger MA; DeWeese TL
Urology; 2007 Mar; 69(3):526-31. PubMed ID: 17382158
[TBL] [Abstract][Full Text] [Related]
19. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
20. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer.
Vis AN; Schröder FH; van der Kwast TH
Eur Urol; 2006 Aug; 50(2):258-65. PubMed ID: 16413660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
